PL3631017T3 - Sposoby wykrywania czerniaka - Google Patents

Sposoby wykrywania czerniaka

Info

Publication number
PL3631017T3
PL3631017T3 PL18731615.3T PL18731615T PL3631017T3 PL 3631017 T3 PL3631017 T3 PL 3631017T3 PL 18731615 T PL18731615 T PL 18731615T PL 3631017 T3 PL3631017 T3 PL 3631017T3
Authority
PL
Poland
Prior art keywords
methods
detecting melanoma
melanoma
detecting
Prior art date
Application number
PL18731615.3T
Other languages
English (en)
Polish (pl)
Inventor
Irvin Modlin
Mark Kidd
Ignat Drozdov
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Publication of PL3631017T3 publication Critical patent/PL3631017T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
PL18731615.3T 2017-05-25 2018-05-21 Sposoby wykrywania czerniaka PL3631017T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511058P 2017-05-25 2017-05-25
PCT/US2018/033658 WO2018217627A1 (en) 2017-05-25 2018-05-21 Methods for melanoma detection

Publications (1)

Publication Number Publication Date
PL3631017T3 true PL3631017T3 (pl) 2022-09-26

Family

ID=62620988

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18731615.3T PL3631017T3 (pl) 2017-05-25 2018-05-21 Sposoby wykrywania czerniaka

Country Status (14)

Country Link
US (2) US20180340934A1 (https=)
EP (1) EP3631017B1 (https=)
JP (1) JP7227964B2 (https=)
KR (1) KR102763004B1 (https=)
CN (1) CN111315897B (https=)
AU (1) AU2018273844B2 (https=)
BR (1) BR112019024481A2 (https=)
CA (1) CA3064732A1 (https=)
DK (1) DK3631017T3 (https=)
ES (1) ES2920288T3 (https=)
IL (1) IL270787B2 (https=)
MX (1) MX2019014026A (https=)
PL (1) PL3631017T3 (https=)
WO (1) WO2018217627A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102763004B1 (ko) 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838732A4 (en) * 2005-01-07 2010-07-14 Univ Johns Hopkins BIOMARKER FOR MELANOME
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
AU2007347118B2 (en) * 2006-11-03 2012-11-01 Baylor Research Institute Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
US20100248225A1 (en) * 2006-11-06 2010-09-30 Bankaitis-Davis Danute M Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
EP2488874A4 (en) * 2009-10-13 2013-08-14 Univ Johns Hopkins BIOMARKERS FOR THE IDENTIFICATION OF MELANOMOTUM CELLS
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
EA201590041A1 (ru) * 2012-07-03 2015-04-30 Ратиофарм Гмбх Твердая форма холиновой соли вемурафениба
EP3194618B1 (en) * 2014-09-15 2021-04-21 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
KR102763004B1 (ko) 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법

Also Published As

Publication number Publication date
EP3631017B1 (en) 2022-03-23
CN111315897A (zh) 2020-06-19
IL270787B2 (en) 2023-08-01
CN111315897B (zh) 2024-10-22
ES2920288T3 (es) 2022-08-02
US12399179B2 (en) 2025-08-26
JP2020524524A (ja) 2020-08-20
AU2018273844A1 (en) 2019-12-19
EP3631017A1 (en) 2020-04-08
JP7227964B2 (ja) 2023-02-22
CA3064732A1 (en) 2018-11-29
BR112019024481A2 (pt) 2020-07-14
MX2019014026A (es) 2020-08-03
US20230022236A1 (en) 2023-01-26
AU2018273844B2 (en) 2024-11-14
US20180340934A1 (en) 2018-11-29
KR102763004B1 (ko) 2025-02-04
WO2018217627A1 (en) 2018-11-29
KR20200030034A (ko) 2020-03-19
DK3631017T3 (da) 2022-06-20
IL270787B1 (en) 2023-04-01
IL270787A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
HUE058127T2 (hu) NSA/SA NR mutató jelentése
IL263586B (en) Inhibitors of the menin-mll interaction
IL250123B (en) Identification of fractionated signals
PL3739299T3 (pl) Wykrywanie obiektów
EP3408402A4 (en) MAGNETIC ELECTROCHEMICAL DETECTION
DK3178258T3 (da) Justering af målingsmellemrum og opdagelsessignaler
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
DK3298718T3 (da) Teknikker til signal-forlængelsessignalering
DK3565542T3 (da) Polymorphic forms of rad1901-2hcl
EP3863207C0 (en) COLLISION SIGNAL RESOLUTION
IL272851A (en) Methods of using dipivefrin
IL253889A0 (en) Detection of brain injury
PL3457851T3 (pl) Pochodne sobetiromu
EP3695547C0 (en) PHASE TRACKING REFERENCE SIGNAL
DK3477274T3 (da) Lækagedetektering
PL3123648T3 (pl) Wykrywanie jednoczesnej transmisji wywołań
FI20145128L (fi) Varhainen akuutin kaatumisriskin havaitseminen
EP3717914C0 (en) BIOMARKER DETECTION
IL313083A (en) Terlipressin compositions and their methods of use
EP3398262A4 (en) MICRO-OUTER CHARACTERIZATION AND SELECTION
DK3170017T3 (da) Forbedret signaldetektering og -karakterisering
PL3239588T3 (pl) Sposób wykrywania substancji
IL254502B (en) Solid forms of menaquinols
EP3619947A4 (en) MEASUREMENT CONFIGURATION
DK3483617T3 (da) Fremgangsmåde til latensmåling